Skip to main content
. 2019 Apr 18;2:100024. doi: 10.1016/j.jvacx.2019.100024

Table 5.

Cost-effectiveness of standalone vaccines for ETEC and Shigella, when limited to settings with an ICER less than three times the GDP threshold, by region, 2025–2034. Results from uncertainty analysis are listed below model estimates. Upper and Lower represent 95% uncertainty intervals for each estimate.

AFRO AMRO EMRO SEARO WPRO** GAVI-eligible Global
ETEC vaccination
Number of countries ICER < 3 X GDP 17 3 4 3 19 27
[7; 21] [1; 4] [2; 5] [ND; 3] [6; 24] [10; 34]
Total deaths* averted (1000 s) 45.6 1.0 13.6 0.4 35.0 60.7
[23.6; 71.3] [0.2; 1.5] [2.7; 19.4] [ND; 0.6] [10.0; 59.3] [26.8; 116.1]
Total deaths* averted/100,000 FVC*** 7.2 2.5 4.6 2.2 5.4 6.1
[5.5; 9.9] [1.2; 3.7] [2.8; 6.2] [ND; 3.0] [4.1; 7.6] [3.9; 8.0]
Total DALYs* averted (1000 s) 1,561 35 464 13 1,194 2,073
[807; 2,440] [8; 51] [93; 659] [ND; 19] [341; 2,026] [915; 3,970]
Total DALYs* averted/100,000 FVC*** 246 86 155 76 185 209
[190; 340] [40; 128] [94; 211] [ND; 100] [140; 260] [133; 273]
Vaccination costs (millions US$) 2,259 146 1,055 60 2,295 3,520
[1,550; 2,944] [69; 183] [332; 1,631] [ND; 95] [821; 3,026] [2,333; 7,928]
Vaccination costs/100,000 FVC*** 355,702 356,373 353,238 352,397 356,570 354,931
[274,110; 561,392] [265,267; 557,867] [253,764; 557,408] [ND; 546,333] [274,842; 563,324] [272,039; 561,229]
Administration costs/100,000 FVC*** 98,453 99,057 96,233 95,475 99,234 97,757
[65,886; 125,759] [63,968; 126,238] [60,760; 123,783] [ND; 122,304] [66,462; 127,364] [65,076; 124,893]
Medical costs averted (millions US$) 82 10 43 2 80 137
[34; 127] [3; 17] [7; 62] [ND; 4] [13; 125] [49; 374]
ICER (2016 US$/DALY) 1,395 3,871 2,181 4,474 1,856 1,632
[982; 2,154] [2,479; 9,664] [1,203; 3,681] [ND; 6,655] [1,206; 2,762] [1,449; 2,530]



Shigella vaccination
Number of countries ICER < 3 X GDP 18 3 8 22 29
[8; 23] [1; 4] [5; 8] [10; 27] [14; 37]
Total deaths* averted (1000 s) 52.7 1.1 53.0 76.5 106.8
[27.1; 91.0] [0.2; 1.6] [31.9; 71.9] [41.1; 121.4] [59.4; 188.3]
Total deaths* averted/100,000 FVC*** 7.9 2.6 10.7 10.1 8.8
[6.1; 10.9] [1.2; 3.9] [8.1; 15.2] [8.2; 14.2] [5.3; 11.9]
Total DALYs* averted (1000 s) 1,746 36 1,777 2,556 3,559
[901; 3,010] [8; 53] [1,070; 2,412] [1,377; 4,041] [1,983; 6,255]
Total DALYs* averted/100,000 FVC*** 260 89 357 339 294
[202; 361] [41; 130] [270; 508] [273; 476] [176; 395]
Vaccination costs (millions US$) 2,386 146 1,763 2,693 4,296
[1,650; 3,237] [71; 187] [1,250; 2,426] [1,811; 3,597] [3,030; 9,202]
Vaccination costs/100,000 FVC*** 355,503 356,373 354,360 356,897 355,062
[275,835; 560,639] [268,790; 558,302] [272,641; 560,870] [276,720; 562,627] [273,263; 560,780]
Administration costs/100,000 FVC*** 98,273 99,057 97,243 99,529 97,876
[66,166; 125,794] [64,733; 125,497] [65,110; 124,785] [67,012; 127,662] [65,318; 124,896]
Medical costs averted (millions US$) 98 10 213 184 321
[38; 151] [3; 17] [74; 302] [81; 269] [116; 652]
ICER (2016 US$/DALY) 1,311 3,750 872 981 1,117
[899; 1,960] [2,465; 9,416] [539; 1,260] [713; 1,366] [1,045; 1,687]
*

Total deaths and DALYS are the sum of burden attributed to diarrhea from ETEC or Shigella infection and ETEC- or Shigella-induced deaths from other infectious diseases.

**

“ND” indicates ‘not defined’ as there were no WPRO countries that met the threshold under the predicted lower bounds (2.5%) of the 95% uncertainty intervals.

***

Fully vaccinated children (FVC): Number of eligible children who received all three doses of the vaccine.